Emergent Biosolutions EBS Deferred Finance Costs Noncurrent Net
Deferred Finance Costs Noncurrent Net at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:DeferredFinanceCostsNoncurrentNet.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's deferred finance costs noncurrent net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's deferred finance costs noncurrent net?
- Emergent Biosolutions (EBS) reported deferred finance costs noncurrent net of $16.1M in Q1 2026.
- How has Emergent Biosolutions's deferred finance costs noncurrent net changed year-over-year?
- Emergent Biosolutions's deferred finance costs noncurrent net decreased by 53.1% year-over-year, from $34.3M to $16.1M.
- What is the long-term trend for Emergent Biosolutions's deferred finance costs noncurrent net?
- Over 5 years (2020 to 2025), Emergent Biosolutions's deferred finance costs noncurrent net has grown at a 10.5% compound annual growth rate (CAGR), from $10.7M to $17.6M.